株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中枢神経系(CNS)バイオマーカーの世界市場の予測

GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FORECAST 2017-2025

発行 Inkwood Research 商品コード 556993
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.33円で換算しております。
Back to Top
中枢神経系(CNS)バイオマーカーの世界市場の予測 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FORECAST 2017-2025
出版日: 2017年09月16日 ページ情報: 英文 110 Pages
概要

当レポートでは、中枢神経系バイオマーカーの世界市場について調査し、全体的な市場動向、用途・タイプ・エンドユーザー・地域別の詳細動向、市場規模の推移と予測、市場の促進要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の決定要因

  • 市場促進要因
  • 市場阻害要因
  • 市場機会
  • 課題

第5章 市場区分

  • 用途別
    • 診断法開発
    • 創薬・薬品開発
    • 個別化医療
    • 疾患リスク評価
    • その他
  • タイプ別
    • 安全性バイオマーカー
    • 薬効バイオマーカー
      • 予測バイオマーカー
      • 薬力学バイオマーカー
      • 予後バイオマーカー
    • 診断バイオマーカー
  • エンドユーザー別
    • 病院
    • 眼科医院
    • 診断センター
    • 患者

第6章 市場分析

  • ファイブフォース分析
  • 主な購買基準
  • 市場機会のマトリクス
  • 戦略提言
  • 結論

第7章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • その他
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東・北アフリカ
    • その他のアフリカ地域

第8章 競合環境

  • 市場シェアの分析
  • 主な成功戦略

第9章 企業プロファイル

  • ACUMEN PHARMACEUTICALS, INC.
  • ALSERES PHARMACEUTICALS INC.
  • APITOPE INTERNATIONAL
  • APOSENSE
  • AVACTA GROUP PLC
  • AVID RADIOPHARMACEUTICALS INC.
  • BANYAN BIOMARKERS.
  • DIAGENIC ASA
  • EKF DIAGNOSTICS
  • ENZO BIOCHEM INC
  • EXONHIT THERAPEUTICS
  • MYRIAD RBM, INC
  • PROTEOME SCIENCES
  • THERMO FISHER SCIENTIFIC
目次
Product Code: 8133

KEY FINDINGS:

The Global Central Nervous System (CNS) Biomarkers market is estimated to rise at a CAGR of 10.49%, increasing its value from $3587 million to $8756 million over the forecast period of 2017-2025. Factors like funding for the research and development framework programs, increasing applications of metabolomics, genomics, bioinformatics and proteomics, and an upsurge in biomarker market are primarily driving the market growth. Also, the fact that obesity has to become a serious concern worldwide and the escalating number of public-private corporations globally are presenting the market with potential growth opportunities.

MARKET INSIGHTS:

The Global Central Nervous System (CNS) Biomarkers market is segmented on the basis of applications, end-users, and types. The various applications include drug discovery and development, diagnostic development, disease risk assessment, personalized medicine, etc. The end-users for the market comprise of patients, hospitals, diagnostic centers, eye clinics, and others. The market by type is further segmented into safety biomarker, validation biomarker, and efficacy biomarker.

REGIONAL INSIGHTS:

The global Central Nervous System (CNS) Biomarkers market geographically covers areas like North America (U.S. & Canada), Asia-Pacific (India, China, Japan, rest of APAC), Europe (UK, France, Germany, Spain, Italy, Rest of Europe) and rest of the world-(Latin America, Middle East and North Africa, Rest of Africa. The North American market is predicted to grab the highest share owing to the booming US market. This boom is on account of the increasing adoption of latest technologies and ongoing research in the area. However, it is the Asia-Pacific market that is forecasted to exhibit the fastest growth over the forecast period.

COMPETITIVE INSIGHTS:

Enzo Biochem, an integrated bioscience company, has been focusing on developing proprietary technologies that deals with applications like oral immune regulation, cell signaling pathway, and gene analysis technology. Another company, Thermo Fisher Scientific Inc provides products and services under five principal brands that include: Applied Bio systems, Fisher Scientific, Invitrogen, Thermo Scientific, and Unity Lab Services. The other eminent market players include Alseres Pharmaceuticals Inc, Acumen Pharmaceuticals Inc, Apitope International Avacta Group Plc, Aposense, Avid Radiopharmaceuticals Inc, Diagenic Asa, Banyan Biomarkers, EKF Diagnostics, Myriad Rbm, Inc (Subsidiary Of Myriad Genetics), Exonhit Therapeutics, and Proteome Sciences.  

tral Nervous System (CNS) market is estimated to rise at a CAGR of 10.49%, increasing its value from $3587 million to $8756 million over the forecast period of 2017-2025. Factors like funding for the research and development framework programs, increasing applications of metabolomics, genomics, bioinformatics and proteomics, and an upsurge in biomarker market are primarily driving the market growth. Also, the fact that obesity has to become a serious concern worldwide and the escalating number of public-private corporations globally are presenting the market with potential growth opportunities.

MARKET INSIGHTS:

The Global Central Nervous System (CNS) market is segmented on the basis of applications, end-users, and types. The various applications include drug discovery and development, diagnostic development, disease risk assessment, personalized medicine, etc. The end-users for the market comprise of patients, hospitals, diagnostic centers, eye clinics, and others. The market by type is further segmented into safety biomarker, validation biomarker, and efficacy biomarker.

REGIONAL INSIGHTS:

The global Central Nervous System (CNS) market geographically covers areas like North America (U.S. & Canada), Asia-Pacific (India, China, Japan, rest of APAC), Europe (UK, France, Germany, Spain, Italy, Rest of Europe) and rest of the world-(Latin America, Middle East and North Africa, Rest of Africa. The North American market is predicted to grab the highest share owing to the booming US market. This boom is on account of the increasing adoption of latest technologies and ongoing research in the area. However, it is the Asia-Pacific market that is forecasted to exhibit the fastest growth over the forecast period.

COMPETITIVE INSIGHTS:

Enzo Biochem, an integrated bioscience company, has been focusing on developing proprietary technologies that deals with applications like oral immune regulation, cell signaling pathway, and gene analysis technology. Another company, Thermo Fisher Scientific Inc provides products and services under five principal brands that include: Applied Bio systems, Fisher Scientific, Invitrogen, Thermo Scientific, and Unity Lab Services. The other eminent market players include Alseres Pharmaceuticals Inc, Acumen Pharmaceuticals Inc, Apitope International Avacta Group Plc, Aposense, Avid Radiopharmaceuticals Inc, Diagenic Asa, Banyan Biomarkers, EKF Diagnostics, Myriad Rbm, Inc (Subsidiary Of Myriad Genetics), Exonhit Therapeutics, and Proteome Sciences.  

TABLE OF CONTENTS

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. ASIA PACIFIC REGIONS HOLD THE POTENTIAL GROWTH OPPORTUNITIES
    • 3.2.2. INCREASING APPLICATION OF BIOMARKERS IN THE DRUG DISCOVERY AND DEVELOPMENT
    • 3.2.3. INCREASE IN NUMBER OF PATIENTS SUFFERING FROM BRAIN TUMOR
    • 3.2.4. EFFICACY BIOMARKER HELD THE LARGEST MARKET SHARE IN 2016

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. INCREASING USAGE OF GENOMICS, METABOLOMICS, PROTEOMICS, AND BIOINFORMATICS
    • 4.1.2. FUNDING BY THE FRAMEWORK PROGRAMS FOR RESEARCH AND DEVELOPMENT OF TECHNOLOGY
    • 4.1.3. OBESITY HAS BECOMING A MAJOR CONCERN
    • 4.1.4. PUBLIC-PRIVATE CORPORATION HAS ESCALATED
    • 4.1.5. UPSURGE IN BIOMARKER MARKET DUE TO FDA SUPPORTS
    • 4.1.6. NEW INNOVATIONS AND TECHNOLOGICAL ADVANCEMENT IN BIOMARKER MARKET
    • 4.1.7. RISE IN REAL PER CAPITA HEALTHCARE
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. REIMBURSEMENT POLICIES DISTRESSING THE CNS BIOMARKER MARKET
    • 4.2.2. CNS BIOMARKER TEST AND DIAGNOSTICS INCLUDES HIGH COST
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. PERSONALIZED MEDICINE PROVIDES NEW WAY FOR DRUG DEVELOPMENT
    • 4.3.2. ASIA PACIFIC IS A HIGH POTENTIAL MARKET FOR CNS BIOMARKER
    • 4.3.3. INCREASING GERIATRIC POPULATION
    • 4.3.4. POLICIES AND FUNDING INITIATIVE TAKEN BY THE GOVERNMENT
  • 4.4. MARKET CHALLENGES
    • 4.4.1. LACK OF AWARENESS REGARDING CNS BIOMARKER
    • 4.4.2. ECONOMIC SLOWDOWN MIGHT DISTRESS THE CNS BIOMARKER MARKET
    • 4.4.3. SAMPLE COLLECTION AND STORAGE IS A MAJOR CHALLENGE

5. MARKET SEGMENTATION

  • 5.1. MARKET BY APPLICATION 2017-2025
    • 5.1.1. DIAGNOSTIC DEVELOPMENT
    • 5.1.2. DRUG DISCOVERY AND DEVELOPMENT
    • 5.1.3. PERSONALIZED MEDICINE MARKET
    • 5.1.4. DISEASE RISK ASSESSMENT
    • 5.1.5. OTHER APPLICATION
  • 5.2. MARKET BY TYPE 2017-2025
    • 5.2.1. SAFETY BIOMARKER
    • 5.2.2. EFFICACY BIOMARKER
      • 5.2.2.1. PREDICTIVE BIOMARKER
      • 5.2.2.2. PHARMACODYNAMICS BIOMARKER
      • 5.2.2.3. PROGNOSTIC BIOMARKER
    • 5.2.3. VALIDATION BIOMARKER
  • 5.3. MARKET BY END USERS 2017-2025
    • 5.3.1. HOSPITALS
    • 5.3.2. EYE CLINICS
    • 5.3.3. DIAGNOSTIC CENTERS
    • 5.3.4. PATIENTS

6. KEY ANALYTICALS

  • 6.1. PORTER'S FIVE FORCE MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. KEY BUYING CRITERIA
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. STRATEGIC RECOMMENDATION
  • 6.5. STRATEGIC CONCLUSIONS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES (U.S.)
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. UNITED KINGDOM (UK)
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. SPAIN
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. INDIA
    • 7.3.2. CHINA
    • 7.3.3. JAPAN
    • 7.3.4. REST OF APAC
  • 7.4. REST OF THE WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST AND NORTH AFRICA
    • 7.4.3. REST OF AFRICA

8. COMPETITIVE LANDSCAPE

  • 8.1. MARKET SHARE ANALYSIS
  • 8.2. TOP WINNING STRATEGIES

9. COMPANY PROFILE

  • 9.1. ACUMEN PHARMACEUTICALS, INC.
    • 9.1.1. COMPANY OVERVIEW
    • 9.1.2. SCOT ANALYSIS
    • 9.1.3. PRODUCT PORTFOLIO
    • 9.1.4. STRATEGIC INITIATIVES
  • 9.2. ALSERES PHARMACEUTICALS INC.
    • 9.2.1. COMPANY OVERVIEW
    • 9.2.2. SCOT ANALYSIS
    • 9.2.3. PRODUCT PORTFOLIO
  • 9.3. APITOPE INTERNATIONAL
    • 9.3.1. COMPANY OVERVIEW
    • 9.3.2. SCOT ANALYSIS
    • 9.3.3. PRODUCT PORTFOLIO
    • 9.3.4. STRATEGIC INITIATIVES
  • 9.4. APOSENSE.
    • 9.4.1. COMPANY OVERVIEW
    • 9.4.2. SCOT ANALYSIS
    • 9.4.3. PRODUCT PORTFOLIO
    • 9.4.4. STRATEGIC INITIATIVES
  • 9.5. AVACTA GROUP PLC
    • 9.5.1. COMPANY OVERVIEW
    • 9.5.2. SCOT ANALYSIS
    • 9.5.3. PRODUCT PORTFOLIO
    • 9.5.4. STRATEGIC INITIATIVES
  • 9.6. AVID RADIOPHARMACEUTICALS INC.
    • 9.6.1. COMPANY OVERVIEW
    • 9.6.2. SCOT ANALYSIS
    • 9.6.3. PRODUCT PORTFOLIO
    • 9.6.4. STRATEGIC INITIATIVES
  • 9.7. BANYAN BIOMARKERS.
    • 9.7.1. COMPANY OVERVIEW
    • 9.7.2. SCOT ANALYSIS
    • 9.7.3. PRODUCT PORTFOLIO
    • 9.7.4. STRATEGIC INITIATIVES
  • 9.8. DIAGENIC ASA
    • 9.8.1. COMPANY OVERVIEW
    • 9.8.2. SCOT ANALYSIS
    • 9.8.3. PRODUCT PORTFOLIO
  • 9.9. EKF DIAGNOSTICS
    • 9.9.1. COMPANY OVERVIEW
    • 9.9.2. SCOT ANALYSIS
    • 9.9.3. PRODUCT PORTFOLIO
    • 9.9.4. STRATEGIC INITIATIVES
  • 9.10. ENZO BIOCHEM INC
    • 9.10.1. COMPANY OVERVIEW
    • 9.10.2. SCOT ANALYSIS
    • 9.10.3. PRODUCT PORTFOLIO
    • 9.10.4. STRATEGIC INITIATIVES
  • 9.11. EXONHIT THERAPEUTICS
    • 9.11.1. COMPANY OVERVIEW
    • 9.11.2. SCOT ANALYSIS
    • 9.11.3. PRODUCT PORTFOLIO
    • 9.11.4. STRATEGIC INITIATIVES
  • 9.12. MYRIAD RBM, INC (SUBSIDIARY OF MYRIAD GENETICS)
    • 9.12.1. COMPANY OVERVIEW
    • 9.12.2. SCOT ANALYSIS
    • 9.12.3. PRODUCT PORTFOLIO
    • 9.12.4. STRATEGIC INITIATIVES
  • 9.13. PROTEOME SCIENCES
    • 9.13.1. COMPANY OVERVIEW
    • 9.13.2. SCOT ANALYSIS
    • 9.13.3. PRODUCT PORTFOLIO
    • 9.13.4. STRATEGIC INITIATIVES
  • 9.14. THERMO FISHER SCIENTIFIC
    • 9.14.1. COMPANY OVERVIEW
    • 9.14.2. SCOT ANALYSIS
    • 9.14.3. PRODUCT PORTFOLIO
    • 9.14.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 GLOBAL CNS BIOMARKER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 2 BIOMARKER DRUG DIAGNOSTIC PRICE
  • TABLE 3 GLOBAL CNS BIOMARKER MARKET BY APPLICATION2017-2025 ($ MILLION)
  • TABLE 4 GLOBAL DIAGNOSTIC DEVELOPMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 5 GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 6 GLOBAL PERSONALIZED MEDICINE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 7 GLOBAL DISEASE RISK ASSESSMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 8 GLOBAL OTHER APPLICATION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 9 GLOBAL CNS BIOMARKER MARKET BY TYPE 2017-2025($ MILLION)
  • TABLE 10 GLOBAL EFFICACY BIOMARKER MARKET 2017-2025($ MILLION)
  • TABLE 11 GLOBAL CNS BIOMARKER MARKET BY END USERS 2017-2025($ MILLION)
  • TABLE 12 NUMBER OF PERSONS WITH OPEN-ANGLE GLAUCOMA IN UNITED STATES, 2015 -2035(MILLION)
  • TABLE 13 GLOBAL CNS BIOMARKER MARKET BY REGION 2017-2025 ($ MILLION)
  • TABLE 14 NORTH AMERICA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • TABLE 15 EUROPE CNS BIOMARKER MARKET 2017-2025
  • TABLE 16 ASIA PACIFIC CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • TABLE 17 PREVALENCE RATE OF DEMENTIA IN REST OF APAC WITH ESTIMATED TREATMENT COST
  • TABLE 18 REST OF WORLD CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • TABLE 19 TOP STRATEGIES

FIGURE LIST

  • FIGURE 1 GLOBAL CNS BIOMARKERS MARKET 2017-2025 ($ MILLION)
  • FIGURE 2 OBESE POPULATION COUNTRIES (%)
  • FIGURE 3 GLOBAL DIAGNOSTIC DEVELOPMENT MARKET 2017-2025 ($ MILLION)
  • FIGURE 4 GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET 2017-2025 ($ MILLION)
  • FIGURE 5 PERSONALIZED MEDICINE IN TERMS OF USAGE
  • FIGURE 6 GLOBAL PERSONALIZED MEDICINE MARKET2017-2025 ($ MILLION)
  • FIGURE 7 GLOBAL DISEASE RISK ASSESSMENT MARKET2017-2025 ($ MILLION)
  • FIGURE 8 GLOBAL OTHER APPLICATION MARKET 2017-2025 ($ MILLION)
  • FIGURE 9 GLOBAL SAFETY BIOMARKER MARKET 2017-2025($ MILLION)
  • FIGURE 10 GLOBAL PREDICTIVE BIOMARKER MARKET 2017-2025($ MILLION)
  • FIGURE 11 GLOBAL PHARMACODYNAMICS BIOMARKER MARKET, 2017-2025($ MILLION)
  • FIGURE 12 GLOBAL PROGNOSTIC BIOMARKER MARKET 2017-2025($ MILLION)
  • FIGURE 13 GLOBAL VALIDATION BIOMARKER MARKET, 2017-2025($ MILLION)
  • FIGURE 14 GLOBAL HOSPITALS CNS BIOMARKER MARKET, 2017-2025,($MILLION)
  • FIGURE 15 GLOBAL EYE CLINICS CNS BIOMARKER MARKET 2017-2025($MILLION)
  • FIGURE 16 GLOBAL DIAGNOSTIC CENTERS CNS BIOMARKER MARKET 2017-2025 ($MILLION)
  • FIGURE 17 GLOBAL NEW CANCER CASES AND MOTILITY RATE 2015 & 2030 (MILLION)
  • FIGURE 18 GLOBAL PATIENTS CNS BIOMARKER MARKET 2017-2025($MILLION)
  • FIGURE 19 PORTER'S FIVE FORCE MODEL IN CNS BIOMARKERS MARKET
  • FIGURE 20 UNITED STATES CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 21 CANADA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 22 UNITED KINGDOM CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 23 FRANCE CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 24 GERMANY CNS BIOMARKER MARKET2017-2025 ($ MILLION)
  • FIGURE 25 SPAIN CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 26 ITALY CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 27 REST OF EUROPE CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 28 PERCENTAGE OF TOTAL POPULATION LIVING WITH DEMENTIA IN REST OF EUROPE
  • FIGURE 29 INDIA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 30 CHINA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 31 JAPAN CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 32 REST OF APAC CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 33 LATIN AMERICA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 34 MENA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 35 REST OF AFRICA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)
  • FIGURE 36 MARKET SHARE ANALYSIS OF CNS MARKET (2016)
Back to Top